QuiaPEG Pharmaceuticals operates in medical technology. The company has developed a technological platform that is used to improve and develop existing pharmaceuticals. The technology is based on what is known as PEGylation, a technique that connects water-soluble polymers with the pharmaceuticals and is used to improve various characteristics in the biopharmaceuticals in regards to stability and resistance.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Bio Vitos Norge AS | 25,30 | 25,30 | 2024-12-20 |
| Bo Nordlander | 7,53 | 7,53 | 2025-03-27 |
| Norvolt AS | 6,28 | 6,28 | 2025-03-27 |
| Södra Långudden förvaltning AB | 4,98 | 4,98 | 2025-03-27 |
| Johan Keisu | 2,03 | 2,03 | 2025-03-27 |
| Gunnela Kristina M Blomqvist | 1,43 | 1,43 | 2025-03-27 |
| Olle Svedåker | 1,42 | 1,42 | 2025-03-27 |
| Jeanette Fogelberg | 1,36 | 1,36 | 2025-03-27 |
| Sami Sinno | 1,35 | 1,35 | 2025-03-27 |
| Martin Berglund | 1,17 | 1,17 | 2025-03-27 |
